Camp Lejeune Veterans Win Justice
On Wednesday, Aug. 10, President Joe Biden signed the comprehensive Honoring Our PACT Act of 2022 into law, allowing military veterans and families harmed by contaminated water at Marine Corps Base Camp Lejeune to file lawsuits against the federal government.
The Camp Lejeune Justice Act of 2022, which focuses on four decades of water contamination, is just one part of the much broader PACT Act, which expands access to health care and disability benefits for veterans harmed by toxic exposures around the world.
Biden lauded the bipartisan support for the PACT Act at the signing.
“There are a lot of issues we can...
Source: Asbestos and Mesothelioma News - August 10, 2022 Category: Environmental Health Authors: Chris Elkins Tags: Veterans Source Type: news
Caregivers of Multiple Myeloma Patients Face Mental Health Issues
TUESDAY, Aug. 2, 2022 -- Many caregivers of patients with multiple myeloma (MM) report mental health challenges, according to a study published online July 18 in Blood Advances.
Elizabeth K. O ' Donnell, M.D., from the Massachusetts General Hospital... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 2, 2022 Category: Pharmaceuticals Source Type: news
Quadruplet Tx in Myeloma May Reduce Need for Transplants Quadruplet Tx in Myeloma May Reduce Need for Transplants
Novel quadruplet combinations are transforming therapy in multiple melanoma and pointing towards a reduced need for stem cell transplants.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 27, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody TECVAYLI ® (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
BEERSE, Belgium, 22 July 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation (CMA) for TECVAYLI® (teclistamab) as monotherapy for adult patients with relapsed and refractory multiple myeloma (RRMM), who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. Teclistamab is an off-the-shelf, T-cell r...
Source: Johnson and Johnson - July 22, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication
Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022
NEWTON, Mass. and FLORENCE, Italy,... Biopharmaceuticals, Oncology, Regulatory Karyopharm Therapeutics, Menarini Group, NEXPOVIO , selinexor, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 21, 2022 Category: Pharmaceuticals Source Type: news
A - Fib Linked to Worse Hospital Outcomes in Multiple Myeloma
In stratified analysis, odds of all - cause mortality, hospital stay of more than five days higher for MM patients not using anticoagulation (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 20, 2022 Category: Cancer & Oncology Tags: Cardiology, Oncology, Journal, Source Type: news
A-Fib Linked to Worse Hospital Outcomes in Multiple Myeloma
WEDNESDAY, July 20, 2022 -- Overall, 13.1 percent of hospitalized patients with multiple myeloma (MM) have atrial fibrillation, which is associated with worse outcomes, according to a study recently published in Cureus.
Inimfon Jackson, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2022 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports Q2 2022 Results
New Brunswick, N.J. (July 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2022. “Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, Chief Executive Officer. “I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world.”OVERALL FINANCIAL RESULTS
expand
...
Source: Johnson and Johnson - July 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Patients Waiting Months for'Last Chance' CAR T-Cell Therapy Patients Waiting Months for'Last Chance' CAR T-Cell Therapy
Supply shortages and limited manufacturing capacity are leaving myeloma patients waiting months for CAR T-cell therapy, which offers a"last chance" after all other therapies have failed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 14, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma
June 29, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for talquetamab for the treatment of adult patients with relapsed or refractory multiple myeloma, who have previously received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Talquetamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting both GPRC5D, a novel drug target, on multiple myeloma cells and CD3 o...
Source: Johnson and Johnson - June 29, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Multiple Myeloma Highlights From ASCO 2022 Multiple Myeloma Highlights From ASCO 2022
Dr Jonathan Kaufman reviews key studies on multiple myeloma presented at ASCO 2022, including the phase 3 DETERMINATION trial, a quadruple induction therapy study, and updated results from MajesTEC-1.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
Machine learning, radiomics differentiates glioma
An automated method based on a machine-learning algorithm and MRI radiomic...Read more on AuntMinnie.comRelated Reading:
SIIM: Neck pain in the radiology reading room? Consider the 'Han Solo' approach
SIIM: AI can detect multiple myeloma lesions on whole-body CT
Deep learning classifies brain tumors on single MRI scans
MRI, histopathologic features boost glioma survival prediction accuracy
AI can identify sarcopenia in glioblastoma patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 28, 2022 Category: Radiology Source Type: news
Antibody Response to COVID-19 Vaccine in Multiple Myeloma Antibody Response to COVID-19 Vaccine in Multiple Myeloma
Are COVID-19 vaccines effective in producing antibody response in patients with multiple myeloma and other monoclonal gammopathies?Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2022 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Whole-body PET/CT for a child: 5 minutes, no sedation
Danish nuclear medicine physicians recently tested a new whole-body PET/CT scanne...Read more on AuntMinnie.comRelated Reading:
New PET/CT scanners may offer safer imaging in children
AI software could help cut PET scan times in half
PET/CT reveals heart artery inflammation in COVID-19 patients
PET visualizes early atherosclerosis
PET/CT predicts treatment outcomes in myeloma patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 27, 2022 Category: Radiology Source Type: news
New CAR-T Therapy Elicits Strong Response in Multiple Myeloma New CAR-T Therapy Elicits Strong Response in Multiple Myeloma
In a small study, one infusion of the investigational CAR T-cell therapy led to a complete response in most patients with no CAR-T-related neurotoxicity.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
